What's Happening?
OrganaBio has opened a new facility in San Diego for the isolation and cryopreservation of peripheral blood mononuclear cells (PBMCs), crucial for cell and gene therapies. The facility, located at Excellos Labs, allows for PBMC processing within three
to four hours of collection, significantly reducing the time and quality loss associated with shipping live material. This rapid processing ensures high cell viability and consistency, crucial for the development of immunotherapies and vaccines. The facility is part of OrganaBio's strategy to provide robust local sourcing for PBMCs, reducing supply chain risks and enhancing manufacturing timelines.
Why It's Important?
The ability to quickly process and preserve PBMCs locally is a significant advancement for the cell and gene therapy industry. It ensures higher quality starting materials, which are essential for the efficacy of therapies. This development is particularly beneficial for biotherapeutic developers in San Diego, a major hub for cell and gene therapy. By reducing the risks associated with transportation and cold-chain logistics, OrganaBio's facility supports the scalability and reliability of cell therapy manufacturing, potentially accelerating the development and availability of new treatments.
